NCT04140604View on ClinicalTrials.gov

Safety Evaluation of Lactobacillus Salivarius AP-32 and Bifidobacterium Animalis Subsp. Lactis CP-9 in Healthy Infants.

NACompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Safety Issues
Interventions
OTHER

Lactobacillus salivarius AP-32

Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.

OTHER

Bifidobacterium animalis subsp. lactis CP-9

Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.

OTHER

Placebo

Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.

Trial Locations (1)

802

Glac Biotech Co., Ltd, Tainan City

All Listed Sponsors
lead

Hsieh-Hsun Ho

INDUSTRY

NCT04140604 - Safety Evaluation of Lactobacillus Salivarius AP-32 and Bifidobacterium Animalis Subsp. Lactis CP-9 in Healthy Infants. | Biotech Hunter | Biotech Hunter